Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes

Last updated: December 10, 2024
Sponsor: University Hospital, Limoges
Overall Status: Active - Recruiting

Phase

N/A

Condition

Brain Cancer

Cancer/tumors

Neurofibromatosis

Treatment

Blood sampling

Clinical Study ID

NCT06116903
87RI22_0011-ExoGLIE
  • Ages > 18
  • All Genders

Study Summary

The purpose of this pilot study is that exosomes constitute a more interesting support for analyzes allowing a broader screening of molecular alterations to be carried out with more reliable, more sensitive and more efficient results than the reference Foundation One Liquid CDx test.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subject of both sexes at least 18 years of age with glioblastoma.

  • Patient for whom an FMI test is indicated, progressing after a 1st line followingthe chemotherapy and radiotherapy protocol (STUPP protocol)

  • Patient affiliated to French social security

Exclusion

Exclusion Criteria:

  • Patient included in another research protocol using an experimental molecule.

  • Any medical or psychiatric condition which, in the Investigator's opinion, wouldpreclude the patient from adhering to the protocol or completing the study perprotocol

  • Patient under legal protection, guardianship or curatorship

  • Patient with active malignancy or a previous malignancy within the past 5 years;except for patient with resected Basocarcinoma and resected carcinoma in-situ of thecervix.

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Blood sampling
Phase:
Study Start date:
April 11, 2024
Estimated Completion Date:
December 15, 2025

Study Description

Gliomas are the most common primary brain tumors in adults. The heterogeneity of tumors, the lack of reliable criteria for identifying different subtypes make their histopathological diagnosis and their management complex. The molecular profiling from circulating exosomes is one of the most promising approaches to better characterize gliomas.

We will demonstrate the superiority of detection by NGS of molecular abnormalities present in exosomes from glioblastomas, compared to detection by the Foundation One Liquid CDx test on ctDNA.

Connect with a study center

  • CHU de Limoges

    Limoges, 87042
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.